Literature DB >> 17455364

Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics.

Anthony J Hickey1, Heidi M Mansour, Martin J Telko, Zhen Xu, Hugh D C Smyth, Tako Mulder, Richard McLean, John Langridge, Dimitris Papadopoulos.   

Abstract

Characteristics of particles included in dry powder inhalers is extended from our previous report (in this journal) to include properties related to their dynamic performance. The performance of dry powder aerosols for pulmonary delivery is known to depend on fluidization and dispersion which reflects particle interactions in static powder beds. Since the solid state, surface/interfacial chemistry and static bulk properties were assessed previously, it remains to describe dynamic performance with a view to interpreting the integrated database. These studies result in complex data matrices from which correlations between specific properties and performance may be deduced. Lactose particles were characterized in terms of their dynamic flow, powder and aerosol electrostatics, and aerodynamic performance with respect to albuterol aerosol dispersion. There were clear correlations between flow properties and aerosol dispersion that would allow selection of lactose particles for formulation. Moreover, these properties can be related to data reported earlier on the morphological and surface properties of the carrier lactose particles. The proposed series of analytical approaches to the evaluation of powders for inclusion in aerosol products has merit and may be the basis for screening and ultimately predicting particle performance with a view to formulation optimization. (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17455364     DOI: 10.1002/jps.20943

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

1.  Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.

Authors:  Xiaojian Li; Frederick G Vogt; Don Hayes; Heidi M Mansour
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-02-06       Impact factor: 2.849

2.  Effect of Particle Formation Process on Characteristics and Aerosol Performance of Respirable Protein Powders.

Authors:  Ashlee D Brunaugh; Tian Wu; Sekhar R Kanapuram; Hugh D C Smyth
Journal:  Mol Pharm       Date:  2019-08-26       Impact factor: 4.939

Review 3.  Process optimization and particle engineering of micronized drug powders via milling.

Authors:  A Brunaugh; H D C Smyth
Journal:  Drug Deliv Transl Res       Date:  2018-12       Impact factor: 4.617

4.  Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.

Authors:  Nivedita Shetty; Patricia Ahn; Heejun Park; Sonal Bhujbal; Dmitry Zemlyanov; Alex Cavallaro; Sharad Mangal; Jian Li; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2018-08-03       Impact factor: 4.939

5.  High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.

Authors:  Samantha A Meenach; Kimberly W Anderson; J Zach Hilt; Ronald C McGarry; Heidi M Mansour
Journal:  AAPS PharmSciTech       Date:  2014-08-20       Impact factor: 3.246

6.  Investigation of electrostatic behavior of a lactose carrier for dry powder inhalers.

Authors:  Keat Theng Chow; Kewu Zhu; Reginald B H Tan; Paul W S Heng
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

7.  Studies on the effect of the size of polycaprolactone microspheres for the dispersion of salbutamol sulfate from dry powder inhaler formulations.

Authors:  Rinku A Tuli; Graeme A George; Tim R Dargaville; Nazrul Islam
Journal:  Pharm Res       Date:  2012-05-15       Impact factor: 4.200

Review 8.  Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.

Authors:  Miriam Braunstein; Anthony J Hickey; Sean Ekins
Journal:  Pharm Res       Date:  2019-10-24       Impact factor: 4.200

9.  Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery.

Authors:  Xiao Wu; Weifen Zhang; Don Hayes; Heidi M Mansour
Journal:  Int J Nanomedicine       Date:  2013-03-24

10.  Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery.

Authors:  Jinghua Duan; Frederick G Vogt; Xiaojian Li; Don Hayes; Heidi M Mansour
Journal:  Int J Nanomedicine       Date:  2013-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.